Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Aggregated data can hide disparities in cancer incidence and outcomes among Asian and Native Hawaiian/Pacific Islander patients in the US.
SBRT prior to sorafenib improved outcomes, compared with sorafenib alone, in a phase 3 trial of patients with advanced hepatocellular carcinoma.
The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.
Cell-free DNA fragmentome analysis can be used to detect hepatocellular carcinoma, according to researchers.
Patients who underwent robotic liver resection had shorter hospital stays and were less likely to be admitted to the ICU than patients who underwent open liver resection.
Adding stereotactic body radiation therapy to sorafenib improves survival outcomes in patients with advanced hepatocellular carcinoma, a phase 3 trial suggests.
The FDA has approved Imjudo (tremelimumab) in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma.
Adding pembrolizumab to lenvatinib does not improve outcomes in patients with advanced hepatocellular carcinoma, results of the LEAP-002 study suggest.
Final results from the RATIONALE-301 trial suggest tislelizumab is noninferior to sorafenib for first-line treatment of unresectable hepatocellular carcinoma.